Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Plasma cell 1

Conditions

Lymphoma 551Precursor Cell Lymphoblastic Leukemia-Lymphoma 511Lymphoma, Non-Hodgkin 439Lymphoma, Follicular 407Lymphoma, Large B-Cell, Diffuse 392Leukemia, Lymphocytic, Chronic, B-Cell 392Lymphoma, B-Cell 249Lymphoma, Mantle-Cell 224Hodgkin Disease 209Recurrence 206Leukemia, Myeloid, Acute 199Leukemia 197Multiple Myeloma 186Burkitt Lymphoma 185Lymphoma, B-Cell, Marginal Zone 170Neoplasms 153Myelodysplastic Syndromes 134Hematologic Neoplasms 115Waldenstrom Macroglobulinemia 103Lymphoma, T-Cell, Peripheral 86Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 83Lymphoma, T-Cell 82Lymphoma, T-Cell, Cutaneous 67Leukemia, Myelogenous, Chronic, BCR-ABL Positive 63Mycosis Fungoides 57Leukemia, Biphenotypic, Acute 55Breast Neoplasms 55Leukemia, B-Cell 52Myeloproliferative Disorders 50Lymphoproliferative Disorders 47

Interventions

gamma-Globulins 1Saline Solution 1Panzyga 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Agammaglobulinemia × Lymphoid × 1 year × Clear all
NCT04502030 2026-06-04

Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

Octapharma

Phase 3 Completed
247 enrolled
LymphoidOther hematologic neoplasm

Agammaglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05645107 2026-04-13

EXCELL

Grifols Therapeutics LLC

Phase 3 Recruiting
386 enrolled
LymphoidOther hematologic neoplasm

Agammaglobulinemia, Bacterial Infections, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡